+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii



In vitro evaluation of the antimicrobial activity of meropenem in combination with polymyxin B and gatifloxacin against Pseudomonas aeruginosa and Acinetobacter baumannii



Journal of ChemoTherapy 20(2): 180-185



The antimicrobial activity of meropenem combined with either polymyxin B or gatifloxacin was evaluated by the checkerboard method against Pseudomonas aeruginosa (10 strains) and Acinetobacter baumannii (10 strains). In addition, the triple combination of polymyxin B, gatifloxacin, and meropenem was also studied as well as the polymyxin B and gatifloxacin combination. A partial synergism interaction between meropenem and polymyxin B was observed for 80% of the A. baumannii strains. In contrast, this combination showed an indifferent effect for 80% of the P. aeruginosa strains tested. The combination of meropenem and gatifloxacin showed synergism only for two strains of A. baumannii, and partial synergism and additive effect for seven strains and indifference for four strains of both species. For the strains of P. aeruginosa, the double combination of polymyxin B and gatifloxacin and the triple combination of meropenem, polymyxin B and gatifloxacin were indifferent for the majority of the strains tested, that is, 90 and 80% respectively.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 031859888

Download citation: RISBibTeXText

PMID: 18467243

DOI: 10.1179/joc.2008.20.2.180


Related references

Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrobial Agents and ChemoTherapy 59(10): 6575-6580, 2015

In vitro activity of beta-lactam antimicrobial agents in combination with aztreonam tested against metallo-beta-lactamase-producing Pseudomonas aeruginosa and Acinetobacter baumannii. Journal of ChemoTherapy 17(6): 622-627, 2005

Activity of meropenem with and without ciprofloxacin and colistin against Pseudomonas aeruginosa and Acinetobacter baumannii. Antimicrobial Agents and ChemoTherapy 52(1): 333-336, 2008

In Vitro Activity of the Novel Antimicrobial Peptide Dendrimer G3KL against Multidrug-Resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Antimicrobial Agents and ChemoTherapy 59(12): 7915-7918, 2015

Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments. Infectious Diseases 49(7): 521-527, 2017

Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model. Antimicrobial Agents and ChemoTherapy 63(1):, 2019

Combination of polymyxin B and meropenem eradicates persister cells from Acinetobacter baumannii strains in exponential growth. Journal of Medical Microbiology 66(8): 1257-1260, 2017

Pharmacodynamics of meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. PharmacoTherapy 24(1): 8-15, 2004

In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampin against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrobial Agents and ChemoTherapy 54(6): 2732-2734, 2010

Evaluation of Vitek2 and BD Phoenix in antimicrobial susceptibility testing of Acinetobacter baumannii and Pseudomonas aeruginosa. Diagnostic Microbiology and Infectious Disease 67(4): 384-386, 2010

Mutant prevention concentrations of imipenem and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii. Thescientificworldjournal 2014: 979648, 2014

Antimicrobial activity of a novel aminoglycoside, ACHN-490, against Acinetobacter baumannii and Pseudomonas aeruginosa from New York City. Journal of Antimicrobial ChemoTherapy 66(2): 332-334, 2011

Mutant prevention concentrations of colistin used in combination with other antimicrobial agents against Acinetobacter baumannii, Klebsiella pneumoniae and Pseudomonas aeruginosa clinical isolates. International Journal of Antimicrobial Agents 44(5): 475-476, 2014

In vitro activity of sulbactam in combination with imipenem, meropenem, panipenem or cefoperazone against clinical isolates of Acinetobacter baumannii. International Journal of Antimicrobial Agents 41(4): 400-401, 2013

In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore. Plos one 6(4): E18485, 2011